The mean systolic blood pressure (SBP) at baseline for Black and White patients not taking antihypertensive medication was 130.7 and 124.2 mm Hg, respectively. For those taking the drugs, mean SBP was ...

Q3 2025 Earnings Call November 12, 2025 8:00 AM ESTCompany ParticipantsHeather Hunter - Senior VP & COOMark Strobeck ...

LivaNova (Nasdaq: LIVN) today announced its new strategic roadmap and long-range financial plan at its 2025 Investor Day.

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...

An ultra-long-acting GLP-1 was tied to weight loss of up to 12.5% at 28 weeks among adults with overweight or obesity with no ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan.

A new study undertaken by the Medical Research Institute of New Zealand (MRINZ) shows that adults with asthma can safely simplify their treatment, reduce overall steroid exposure and improve asthma ...

If you have been prescribed lisdexamfetamine dimesylate capsules to treat ADHD, you should know the FDA has recalled several lots of this medication.

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsBrian Luque - Head of Investor Relations & ...

The company has established a pathway to achieve this growth by maximizing its core businesses, scaling Obstructive Sleep Apnea, and preserving ...

Alto Neuroscience, Inc. ("Alto") a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for ...

Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA®– Q3 2025 operating profit of €11.0 million– TransCon® ...